Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK Science in the Summer™ Returns Virtually for Summer 2020 in Partnership with The Franklin Institute
GSK Science in the Summer™ returns this summer as an entirely virtual offering with a new theme: Be a Chemist!
-
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
-
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
-
GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel
Voltaren Arthritis Pain Gel partners with Paula Abdul to launch prescription-strength NSAID gel for arthritis pain available OTC
-
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase
-
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
Press release
-
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study
-
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
Announcement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
-
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
GSK announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme
-
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
An approval would give Nucala a third indication in an eosinophil-driven disease
-
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing.
-
GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020
26 abstracts across 8 tumour types, advancing GSK’s goal of maximising outcomes for patients
-
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Ovarian cancer press release
-
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
-
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress
-
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
-
Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis
Voltaren Arthritis Pain will donate 100% of pre-order profits up to $100k to the Arthritis Foundation
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
-
Update on GSK actions to support the global response to COVID-19
As a leader in science and innovation, we are contributing to the fight against COVID-19 with our advanced vaccine adjuvant systems.
-
GSK appoints Charles Bancroft to the Board as a Non-Executive Director
GlaxoSmithKline plc today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
